⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 13, 2017Journal of Nuclear MedicineOpen Access

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Clemens Kratochwil Frank Bruchertseifer Hendrik Rathke Marcus Bronzel Christos Apostolidis Wilko Weichert Uwe Haberkorn Frederik L. Giesel Aliyah Morgenstern

View Full Paper

Ask AI

Bookmark

Share

Abstract

Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kratochwil et al. (2017) studied this question.

synapsesocial.com/papers/6a013ade6018b8d0892dedec https://doi.org/10.2967/jnumed.117.191395

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>177</sup>Lu-Labeled PSMA-617Original Research · 2016 · 631 citations
2German Multicenter Study Investigating<sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsRetrospective Study · 2016 · 832 citations
3Systemic Radioligand Therapy with <sup>177</sup> Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate CancerRetrospective Study · 2016 · 187 citations
4213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceRetrospective Study · 2014 · 407 citations
5Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane AntigenIn Vitro Study · 2015 · 112 citations

More related papers

(2<i>S</i>)-2-(3-(1-Carboxy-5-(4-<sup>211</sup>At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy2016
Radiometabolic Treatment of Bone-Metastasizing Cancer: From <sup>186</sup> Rhenium to <sup>223</sup> Radium2013
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer2016

More from Journal of Nuclear Medicine

TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of 212 Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation–Resistant Prostate CancerFri,
Delta-like Ligand 3–Targeted Imaging in Small Cell Lung CancerThu,